CN102327289B - Erythrocyte freeze-dried powder preparation for injection and preparation method thereof - Google Patents
Erythrocyte freeze-dried powder preparation for injection and preparation method thereof Download PDFInfo
- Publication number
- CN102327289B CN102327289B CN201110312734A CN201110312734A CN102327289B CN 102327289 B CN102327289 B CN 102327289B CN 201110312734 A CN201110312734 A CN 201110312734A CN 201110312734 A CN201110312734 A CN 201110312734A CN 102327289 B CN102327289 B CN 102327289B
- Authority
- CN
- China
- Prior art keywords
- erythrocyte
- injection
- freeze
- cell
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to an erythrocyte freeze-dried powder preparation for injection and a preparation method thereof. The erythrocyte freeze-dried powder preparation is characterized in that a freezing protective agent is composed of an impermeable protective agent and tetrahydropyrimidine or hydroxyl tetrahydropyrimidine. The erythrocyte freeze-dried powder preparation for injection has high safety, strong stability, higher recovery rate and in-vivo survival time and better erythrocyte functions; and the freeze drying has extremely low influence on erythrocytes, thereby facilitating the long-term storage and transport of erythrocytes.
Description
Technical field
The present invention relates to a kind of injection freeze-dried powder preparation, particularly a kind of erythrocytic injection freeze-dried powder preparation.
Background technology
Erythrocyte mainly is made up of cell membrane and hemoglobin, is the important component of blood, and major function is delivering oxygen and carbon dioxide.In the higher pulmonary of partial pressure of oxygen, hemoglobin and oxygen are combined into HbO2 Oxyhemoglobin, flow to the lower tissue of partial pressure of oxygen with blood then; Hemoglobin is separated, and the oxygen that carries is discharged, and combines with the carbon dioxide that tissue is produced again; Be transported to pulmonary, excrete.Human body needs supplemental blood behind massive blood loss.Popularization along with component blood transfusion technology needn't replenish whole blood after losing blood, gets final product but give blood constitutent such as a certain amount of erythrocyte.
Therefore, erythrocytic external preservation and bioactive maintenance become the technological precursor of component blood transfusion technology.Mainly contain fluid preservation method, freeze preservation and freeze-drying with erythrocytic store method at present.Wherein liquid processes generally refers to 4 ℃ of cryopreservation methods, and freezing preservation refers to-80 ℃ or-196 ℃ of profound hypothermia preservations.Freeze-drying be with its suitably dehydration than liquid processes and freezing method remarkable advantages is arranged after drying is processed, its goods can room temperature preservation, is easy to aquation, weight alleviates greatly, is convenient to transport, and cuts the waste.At present, the fluid preservation erythrocyte has been widely used in clinical, and obtains constantly perfect; Freezing preservation erythrocyte has begun to be applied to clinical; Erythrocytic technology immaturity is still preserved in lyophilization, lacks practicality.
The research that erythrocyte is preserved is extremely paid attention to.The length of its storage life has become an important indicator weighing a national clinical blood transfusion level.Research is at present thought, adopts freeze drying technology can prolong erythrocytic storage life, and crucial adjuvants such as cryoprotective agent commonly used in the research comprise trehalose, dimethyl sulfoxide, polyvinylpyrrolidone and bovine serum albumin etc.
Trehalose is a kind of stable irreducibility disaccharidase, and its hydroxyl can replace hydrone partly to combine with protein surface, can form protective layer behind the entering cell, and pair cell forms protection.But have only when trehalose reaches finite concentration and be evenly distributed on inside and outside the cell membrane, could in freeze-drying process, play a protective role erythrocyte.Therefore, the payload trehalose is that one of chief factors of success are preserved in the erythrocyte lyophilizing to born of the same parents before the lyophilizing.Therefore yet erythrocyte membrane has impermeability to trehalose, the trehalose load is got in the erythrocyte born of the same parents, needs complicated technical process, consuming timely reaches 4 hours, and needs to introduce more kinds of chemical substances.Make technological problems and safety issue become one of difficult problem of puzzlement erythrocyte lyophilized powder application.
Dimethyl sulfoxide can prevent to form in the freeze-drying process ice crystal pair cell and cause damage.Temperature is during near 0 ℃, and dimethyl sulfoxide descends the freezing point of solution, no ice crystal formation; When temperature continues to reduce, form ice crystal in the extracellular fluid, and solution does not freeze in the erythrocyte.The outer water of erythrocyte born of the same parents constantly forms ice crystal, and born of the same parents' extracellular concentration increases, and intracellular Free water permeate through cell membranes is exuded to outside the born of the same parents, if cooling rate is enough slow, erythrocyte is dewatered gradually and can not forms ice crystal.But; Dimethyl sulfoxide is as a kind of chemical reagent; Human body is had certain toxic action, be inappropriate for drug administration by injection, residual dimethyl sulfoxide may accumulate gradually in the long-term erythrocytic patient's body of infusion lyophilizing and form injury; So need flushing repeatedly before using, thereby problem that causes the erythrocyte response rate to reduce.
Polyvinylpyrrolidone is similar with trehalose, is the impermeability cytoprotective, and FD is had the certain protection effect.Bovine serum albumin then is a kind of film protective agent.
Results of laboratory is thought at present, and in the erythrocyte freeze-drying process, needing trehalose, polyvinylpyrrolidone, bovine serum albumin combination to use could be to the effect of the performance of the erythrocyte in freeze-drying process certain protection.And needing dimethyl sulfoxide effectively to get into cell, trehalose plays a role.And, the at present various erythrocyte freeze-dry process and the prescription of research and development, because of complicated component, there are problems such as the erythrocyte response rate is low, the variation of lyophilizing red cell morphology, the active reduction of lyophilizing red blood cell enzyme in reason such as technological parameter is wayward.Therefore, seek new safely and can keep lyophilizing erythrocyte high-recovery and highly active erythrocyte lyophilized powder prescription and technology, become the key factor that has become the clinical use of restriction erythrocyte.
Tetrahydropyrimidine, chemistry by name 1,4,5; 6-tetrahydrochysene-2-methyl-4-pyrimidine carboxylic or 2-Methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid or (S)-2-methyl-1; 4,5,6-tetra-hydro pyrimidine-4-carboxylic acid or 1,4; 5,6-tetrahydro-2-methyl-4-pyrimidine carbonic acid, CAS number is 96702-03-3; Be the amino acid derivativges of finding in the marine organism in 1985, have preserve moisture, effect such as anti-ultraviolet irradiation, be used to cosmetics in recent years as moisture retention composition or adjuvant.
Summary of the invention
To above-mentioned prior art, the object of the present invention is to provide a kind of injection freeze-dried powder preparation, a kind of specifically injection erythrocyte freeze-dried powder preparation.
On the other hand, the present invention also provides a kind of method for preparing of injection erythrocyte freeze-dried powder preparation.
For realizing above-mentioned purpose, the technical scheme that the present invention adopts is:
A kind of injection erythrocyte freeze-dried powder preparation; Form by erythrocyte and cryoprotective agent; Said cryoprotective agent is made up of impermeability cryoprotective agent and tetrahydropyrimidine or hydroxy tetrahydro pyrimidine, and said impermeability cryoprotective agent is selected from any one in polyvinylpyrrolidone, bovine serum albumin and the trehalose; Said tetrahydropyrimidine or hydroxy tetrahydro pyrimidine consumption are per 10
12Individual erythrocyte cell is used 5mg-80mg, and the consumption of said impermeability cryoprotective agent is per 10
12Individual erythrocyte cell is used 2mg-50mg.
The consumption of said tetrahydropyrimidine or hydroxy tetrahydro pyrimidine is per 10
12Individual erythrocyte cell is used 10mg-30mg.
The consumption of said impermeability cryoprotective agent is per 10
12Individual erythrocyte cell is used 2mg-20mg.
Said impermeability cryoprotective agent is a polyvinylpyrrolidone.
The consumption of said polyvinylpyrrolidone is per 10
12Individual erythrocyte cell is used 2mg-14mg.
The method for preparing of said injection erythrocyte freeze-dried powder preparation, step is:
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds impermeability cryoprotective agent and tetrahydropyrimidine or hydroxy tetrahydro pyrimidine then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 7Pa-15Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours;
C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Tetrahydropyrimidine described in the technical scheme of the present invention, chemistry 2-Methyl-1 by name, 4; 5,6-tetrahydropyrimidine-4-carboxylic acid or (S)-2-methyl-1,4; 5,6-tetra-hydro pyrimidine-4-carboxylic acid or 1,4; 5,6-tetrahydro-2-methyl-4-pyrimidine carbonic acid.1,4,5,6-tetrahydrochysene-2-methyl-5-hydroxyl-4-pyrimidine carboxylic is commonly called as the hydroxy tetrahydro pyrimidine, and CAS number is 96702-03-3, and this is that those skilled in the art are known.
The inventor's surprised discovery in experimentation; The mixture of tetrahydropyrimidine and some impermeability cryoprotective agent; The lyophilizing erythrocyte is had unexpected protective effect, and erythrocyte and tetrahydropyrimidine and derivant thereof and impermeability cryoprotective agent mix the back lyophilizing, and the injection erythrocyte freeze-dried powder preparation of gained is safe; Stability is strong; Time-to-live and erythrocytic function are higher relatively in the response rate, the body, and lyophilizing is minimum to erythrocytic influence, is beneficial to erythrocytic long term store and transportation.
Description of drawings
Fig. 1Red cell morphology under the light microscopic after the injection erythrocyte lyophilized powder rehydration of embodiment 9 preparations.
The specific embodiment
Below in conjunction with embodiment the present invention is done further explanation.Should be understood that following examples only are used to explain the present invention, rather than restriction protection scope of the present invention.
Embodiment 1 injection erythrocyte lyophilized powder prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Tetrahydropyrimidine 12mg
Polyvinylpyrrolidone 10mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 1 * 10 with erythrocyte
9The suspension of cell/ml adds tetrahydropyrimidine and polyvinylpyrrolidone then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 12Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 2 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Hydroxy tetrahydro pyrimidine 20mg
Polyvinylpyrrolidone 7mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds hydroxy tetrahydro pyrimidine and polyvinylpyrrolidone then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 9Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 3 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Hydroxy tetrahydro pyrimidine 30mg
Trehalose 45mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds hydroxy tetrahydro pyrimidine and trehalose then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 10Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 4 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Hydroxy tetrahydro pyrimidine 42mg
Bovine serum albumin 18mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds hydroxy tetrahydro pyrimidine and bovine serum albumin then, leaves standstill 1 hour;
2) lyophilizing: a, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 10Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 5 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Tetrahydropyrimidine 26mg
Polyvinylpyrrolidone 10mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds tetrahydropyrimidine and polyvinylpyrrolidone then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 10Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 6 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Tetrahydropyrimidine 58mg
Trehalose 50mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds tetrahydropyrimidine and trehalose then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 12Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃, kept dry 5 hours, promptly get with 0.1 ℃/minute programming rate.
Embodiment 7 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Tetrahydropyrimidine 72mg
Bovine serum albumin 23mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds tetrahydropyrimidine and bovine serum albumin then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 10Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 8 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Tetrahydropyrimidine 60mg
Polyvinylpyrrolidone 3mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds tetrahydropyrimidine and polyvinylpyrrolidone then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 12Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 9 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Tetrahydropyrimidine 15mg
Polyvinylpyrrolidone 12g
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds tetrahydropyrimidine and polyvinylpyrrolidone then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 15Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 10 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Tetrahydropyrimidine 17mg
Polyvinylpyrrolidone 19mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds tetrahydropyrimidine and polyvinylpyrrolidone then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 9Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 11 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Hydroxy tetrahydro pyrimidine 20mg
Polyvinylpyrrolidone 10mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds hydroxy tetrahydro pyrimidine and polyvinylpyrrolidone then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 10Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 12 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Hydroxy tetrahydro pyrimidine 12mg
Bovine serum albumin 15mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds hydroxy tetrahydro pyrimidine and bovine serum albumin then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 10Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 13 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Tetrahydropyrimidine 18mg
Trehalose 59mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds tetrahydropyrimidine and trehalose then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 10Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 14 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Tetrahydropyrimidine 11mg
Trehalose 75mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds tetrahydropyrimidine and trehalose then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 10Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 15 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Tetrahydropyrimidine 11mg
Bovine serum albumin 32mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds tetrahydropyrimidine and bovine serum albumin then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 7Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
Embodiment 16 injection erythrocyte lyophilized powders prescription and preparation
Erythrocyte cell 2 * 10
9Cell/ml 1000ml
Tetrahydropyrimidine 19mg
Trehalose 41mg
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds tetrahydropyrimidine and trehalose then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours; B, primary drying: be evacuated to 10Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours; C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
The acute toxicity testing of embodiment 17 injection erythrocyte freeze-dried powder preparations
SPF level KM mice; Male and female half and half; Body weight 16g-30g is divided into 17 groups at random after weighing, one group of tail vein injection gives not freeze dried erythrocyte; All the other 16 groups respectively intravenous injection give embodiment 1-embodiment 16 prepared lyophilized powder (lyophilized powder redissolves with normal saline), calculating dosage with the erythrocyte number of cells is 10
12/ only, observed 14 days continuously after the administration.Observation item comprises toxic reaction, body weight and histopathology.The result shows that mouse tail vein injection gives the erythrocyte lyophilized powder, counts 10 with the erythrocyte number of cells
14/ the time, the reaction of no overt toxicity, before and after the administration and experiment mice body weight no significant difference when finishing, pathological study is found significantly unusual.Explain that injection erythrocyte freeze-dried powder preparation of the present invention safety is good.
The long term toxicity test of embodiment 18 injection erythrocyte freeze-dried powder preparations
The Wister rat; Male and female half and half; 420g-600g is divided into 17 groups at random after weighing, one group of tail vein injection gives not freeze dried erythrocyte; All the other 16 groups respectively intravenous injection give embodiment 1 to embodiment 16 prepared lyophilized powder (lyophilized powder redissolves with normal saline), calculating dosage with the erythrocyte number of cells is 2 * 10
9/ only, administration was 1 time in per two days, and totally 30 days, convalescent period was 14 days.During the administration and in convalescent period; Observe before the rat administration and after the administration and carry out gross examination of skeletal muscle; The body weight of rat before the general symptom of record rat, the record administration and after the administration, and regularly carry out hematology, urine and blood biochemical analysis reaches the electrocardiogram of rat after the administration before the record administration.The result shows that each treated animal body weight and matched group do not have significant difference, and gross examination of skeletal muscle is no abnormal.The hematology of experimental group animal, urine and blood physicochemical data and matched group do not have significant difference.The safety that four injection erythrocyte freeze-dried powder preparation long term administrations are described is good, and toleration meets the requirement of clinical application.
The erythrocyte response rate of embodiment 19 injection erythrocyte freeze-dried powder preparations
The erythrocyte in vitro cell response rate=(erythrocyte number after the rehydration/lyophilizing proerythrocyte number) * 100%
Embodiment 1-embodiment 16 prepared lyophilized powders are used the normal saline rehydration, number after reaching rehydration before each group erythrocyte cell rehydration is counted, calculate and respectively organize the erythrocyte cell response rate (get for every group and average after three duplicate samples are measured).The result shows; Each erythrocyte in vitro cell response rate (average) of organizing lyophilized powder is 85.7%-96.0%; Wherein the erythrocyte in vitro cell response rate of the lyophilized powder of being made up of tetrahydropyrimidine or hydroxy tetrahydro pyrimidine and polyvinylpyrrolidone of embodiment 1, embodiment 2, embodiment 9 and embodiment 11 preparations concentrates on 87.1%-98.3%, is significantly higher than other and respectively organizes.
Morphological observation after the erythrocyte rehydration of embodiment 20 injection erythrocyte freeze-dried powder preparations
After the injection erythrocyte lyophilized powder that embodiment 1 to embodiment 16 is prepared redissolved with normal saline, the erythrocyte smear was done Ji's nurse Sa dyeing (Giemsa stain), fresh red blood cell behind smear staining equally as normal control; Observation by light microscope is also taken a picture.After the result shows that embodiment 1 to embodiment 16 prepared injection erythrocyte lyophilized powder redissolves with normal saline, the red cell morphology no abnormality seen.Red cell morphology after the embodiment 9 injection erythrocyte lyophilized powder rehydrations is seen Fig. 1.
Adenosinetriphosphataes and glucose-6-phosphate dehydrogenase (G6PD) determination of activity after the erythrocyte rehydration of embodiment 21 injection erythrocyte freeze-dried powder preparations
The injection erythrocyte lyophilized powder that embodiment 1 to embodiment 16 is prepared uses kit measurement adenosinetriphosphataes (ATP) and glucose-6-phosphate dehydrogenase (G6PD) (G-6-PD) activity after redissolving with normal saline.Fresh red blood cell and 2% standard red cell suspension are done same mensuration as contrast.The result sees table 1.
Table 1
| Group | ATP active (10 7/U) | G-6-PD active (%) |
| Fresh red blood cell | 17.5±2.8 | 84.2±5.3 |
| 2% standard red cell suspension | 10.2±5.6 | 59.4±4.7 |
| After the embodiment 1 lyophilizing erythrocyte rehydration | 16.9±3.0 | 83.8±7.4 |
| After the embodiment 2 lyophilizing erythrocyte rehydrations | 17.2±9.5 | 84.0±6.1 |
| After the embodiment 3 lyophilizing erythrocyte rehydrations | 16.6±6.4 | 81.7±3.9 |
| After the embodiment 4 lyophilizing erythrocyte rehydrations | 16.0±5.7 | 82.1±9.4 |
| After the embodiment 5 lyophilizing erythrocyte rehydrations | 18.3±4.1 | 83.5±1.0 |
| After the embodiment 6 lyophilizing erythrocyte rehydrations | 16.6±8.6 | 82.4±6.7 |
| After the embodiment 7 lyophilizing erythrocyte rehydrations | 16.2±6.5 | 81.8±3.2 |
| After the embodiment 8 lyophilizing erythrocyte rehydrations | 17.5±4.4 | 83.0±2.6 |
| After the embodiment 9 lyophilizing erythrocyte rehydrations | 17.1±2.9 | 84.1±6.9 |
| After the embodiment 10 lyophilizing erythrocyte rehydrations | 18.1±0.3 | 83.5±2.8 |
| After the embodiment 11 lyophilizing erythrocyte rehydrations | 17.6±5.2 | 83.2±5.3 |
| After the embodiment 12 lyophilizing erythrocyte rehydrations | 16.8±8.3 | 81.9±6.6 |
| After the embodiment 13 lyophilizing erythrocyte rehydrations | 16.1±4.6 | 81.1±9.7 |
| After the embodiment 14 lyophilizing erythrocyte rehydrations | 16.6±3.1 | 82.4±3.5 |
| After the embodiment 15 lyophilizing erythrocyte rehydrations | 16.0±1.2 | 83.0±4.9 |
| After the embodiment 16 lyophilizing erythrocyte rehydrations | 16.7±3.5 | 80.7±5.1 |
The result shows, the erythrocyte lyophilized powder of embodiment 1 to embodiment 16 preparation, and ATP activity and G-6-PD activity do not have significant difference in fresh red blood cell after the rehydration, significantly are superior to red cell suspension commonly used at present.
Claims (2)
1. injection erythrocyte freeze-dried powder preparation; It is characterized in that: form by erythrocyte and cryoprotective agent; Said cryoprotective agent is made up of any one and the impermeability cryoprotective agent that are selected from tetrahydropyrimidine, hydroxy tetrahydro pyrimidine; Said impermeability cryoprotective agent is selected from any one in polyvinylpyrrolidone, bovine serum albumin and the trehalose, and said tetrahydropyrimidine or hydroxy tetrahydro pyrimidine consumption are per 10
12Individual erythrocyte cell is used 10mg-30mg, and the consumption of said impermeability cryoprotective agent is per 10
12Individual erythrocyte cell is used 2mg-20mg;
This injection erythrocyte freeze-dried powder preparation method for preparing step is:
1) dosing:
With normal saline washing 2 times, using sterilized water for injection to be made into concentration is 2 * 10 with erythrocyte
9The suspension of cell/ml adds tetrahydropyrimidine or hydroxy tetrahydro pyrimidine and impermeability cryoprotective agent then, leaves standstill 1 hour;
2) lyophilizing:
A, pre-freeze: the solution that will be sub-packed in cillin bottle is reduced to-50 ℃ with 10 ℃/minute speed from-20 ℃, keeps freezing 2 hours;
B, primary drying: be evacuated to 7Pa-15Pa, be warming up to-10 ℃ with 5 ℃/minute programming rate then, kept dry 6 hours;
C, redrying: behind the primary drying, be warming up to 25 ℃ with 0.1 ℃/minute programming rate, kept dry 5 hours, the sterilization packing promptly gets.
2. injection erythrocyte freeze-dried powder preparation according to claim 1 is characterized in that: said impermeability cryoprotective agent is a polyvinylpyrrolidone, and the consumption of said polyvinylpyrrolidone is per 10
12Individual erythrocyte cell is used 2mg-14mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110312734A CN102327289B (en) | 2011-10-17 | 2011-10-17 | Erythrocyte freeze-dried powder preparation for injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110312734A CN102327289B (en) | 2011-10-17 | 2011-10-17 | Erythrocyte freeze-dried powder preparation for injection and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102327289A CN102327289A (en) | 2012-01-25 |
| CN102327289B true CN102327289B (en) | 2012-10-03 |
Family
ID=45479420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110312734A Active CN102327289B (en) | 2011-10-17 | 2011-10-17 | Erythrocyte freeze-dried powder preparation for injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102327289B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11815311B2 (en) | 2019-03-14 | 2023-11-14 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106821938B (en) * | 2017-03-21 | 2020-03-24 | 北京海康殷氏生物科技有限责任公司 | Preparation method of human mesenchymal stem cell freeze-dried powder |
| CA3078625C (en) | 2017-10-09 | 2023-01-17 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
| CN115024310B (en) * | 2022-07-19 | 2024-06-18 | 首都医科大学宣武医院 | Cell freeze-drying preservative and preparation method thereof |
| CN115399314B (en) * | 2022-11-01 | 2023-05-19 | 天津德祥生物技术股份有限公司 | Human ABO blood type inverse typing red blood cell capable of being freeze-dried and stored and storage method |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4921052A (en) * | 1972-06-16 | 1974-02-25 | ||
| JPS58131913A (en) * | 1982-01-29 | 1983-08-06 | Green Cross Corp:The | Preparation of lyophilized erythrocyte |
| CN101368172A (en) * | 2008-10-06 | 2009-02-18 | 上海理工大学 | Freeze drying protective agent for rubricyte and use method in freeze drying process |
-
2011
- 2011-10-17 CN CN201110312734A patent/CN102327289B/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11815311B2 (en) | 2019-03-14 | 2023-11-14 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102327289A (en) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102327289B (en) | Erythrocyte freeze-dried powder preparation for injection and preparation method thereof | |
| CN109769797B (en) | Organ preservation solution | |
| RU2146088C1 (en) | Concentrated solution for cryogenic storage (versions), method for cryogenic storage of cells (versions), method for cryogenic storage and regeneration of viable cells, and method for cryogenic storage, regeneration and therapeutic utilization of cells | |
| CN1184883C (en) | Agent and method for preserving animal cells and organs | |
| KR101160198B1 (en) | Method of separating pancreatic islet | |
| US6743575B2 (en) | Compositions and methods for the preservation of living tissues | |
| JPS6360931A (en) | Solution for preserving blood or blood preparation and preservation of blood or blood preparation using said solution | |
| CN112841174A (en) | Cryopreservation liquid for long-term storage of human umbilical cord mesenchymal stem cells | |
| JPH0625066B2 (en) | Platelet storage medium | |
| JPH02186981A (en) | Lyophilization of cell | |
| EP3795674A1 (en) | Composition, cell storage composition, cell culture composition, cell formulation, method for producing object containing microbubble, cell storage method, cell culture method, and cell formulation production method | |
| AU2013328472A1 (en) | Method for preserving placental blood | |
| CN104222069A (en) | Erythroid progenitor cell cryopreservation liquid and application thereof | |
| CN110193025B (en) | Exosome freeze-dried powder derived from human adipose-derived stem cells, and preparation method and application thereof | |
| CN112889810A (en) | Human umbilical cord mesenchymal stem cell injection frozen stock solution and preparation method thereof | |
| EP3346833A1 (en) | Injectable preserving medium for preserving cells from placental blood, from bone marrow and from peripheral blood | |
| EP1875802B1 (en) | Method for preserving pancreatic islet | |
| Beutler et al. | Preservation of red cell 2, 3-DPG and viability in bicarbonate-containing medium: the effect of blood-bag permeability | |
| CN102327288B (en) | Blood platelet freeze-dried powder preparation for injection and preparation method thereof | |
| CN105168236A (en) | Application of nicotinamide adenine dinucleotide in preparation of drug for preventing and treating heart ischemic injuries | |
| Feola et al. | Improved oxygenation of ischemic myocardium by hemodilution with stroma-free hemoglobin solution | |
| US20240060049A1 (en) | Lyophilized mesenchymal stem cells | |
| RU2487704C2 (en) | Method for prevention of reperfusion injuries of donor organs | |
| CN111418577B (en) | Special clinical-grade adipose tissue cryopreservation liquid as well as preparation method, use method and application thereof | |
| JP4590041B2 (en) | Organ preservative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LI BAOQIU Free format text: FORMER OWNER: JINAN HUANTAI PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20150416 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150416 Address after: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 Patentee after: Li Baoqiu Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 Patentee before: Jinan Huantai Pharmaceutical Technology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200713 Address after: No.3787 wangmugong street, Qingzhou Economic Development Zone, Weifang City, Shandong Province Patentee after: Shandong Yizhou Biotechnology Co., Ltd Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 Patentee before: Li Baoqiu |